Home | About us | Editorial Board | Search | Ahead of print | Current Issue | Archives | Instructions | Online submissionContact Us   |  Subscribe   |  Advertise   |  Login  Page layout
Wide layoutNarrow layoutFull screen layout
Lung India Official publication of Indian Chest Society  
  Users Online: 214   Home Print this page  Email this page Small font size Default font size Increase font size
Year : 1986  |  Volume : 4  |  Issue : 2  |  Page : 63-65

Rifampicin And Ascorbic Acid : Role In Anti – Tuberculosis Chemotherapy

Correspondence Address:
S. D Purohit

Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Three hundred and ninety seven smear positive patients of pulmonary tuberculosis were randomly put on two rifampicin containing anti-tuberculosis drug regimens with ascorbic acid and without ascorbic acid. Serum rifampicin levels and hepatotoxicity during the study were assessed. Ascorbic acid did not influence the serum levels of rifampicin (p>0.1). However the frequency of hepatitis was less in patients receiving anti-tuberculosis drugs with ascorbic acid (1.7%) compared to those who received anti-tuberculosis drugs alone (3.7%).

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded132    
    Comments [Add]    

Recommend this journal